Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

by A J van der Wekken, J L Kuiper, A Saber, M M Terpstra, J Wei, T J N Hiltermann, E Thunnissen, D A M Heideman, W Timens, E Schuuring, K Kok, E F Smit, A van den Berg, H J M Groen
Published 2017-01-01

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.

by Gerald S M A Kerner, Ed Schuuring, Johanna Sietsma, Thijo J N Hiltermann, Remge M Pieterman, Gerard P J de Leede, John W G van Putten, Jeroen Liesker, Tineke E J Renkema, Peter van Hengel, Inge Platteel, Wim Timens, Harry J M Groen, CTMM Air Force Consortium
Published 2013-01-01